NeoGenomics (NeoGenomics) Total Current Assets : $573.9 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. NeoGenomics's total current assets for the quarter that ended in Mar. 2024 was $573.9 Mil.

NeoGenomics Total Current Assets Historical Data

The historical data trend for NeoGenomics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Total Current Assets Chart

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

290.74

448.73

681.51

605.29

596.81

NeoGenomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															585.00	584.72	586.95	596.81	573.90

NeoGenomics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

NeoGenomics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	415.203	+	131.227	+	24.156	+	26.226
	=	596.8

NeoGenomics's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	384.83	+	140.279	+	20.32	+	28.467
	=	573.9

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

NeoGenomics (NAS:NEO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

NeoGenomics's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	384.83	-	716.929	+	0.75 * 140.279	+	0.5 * 20.32
=	-216.7

NeoGenomics Total Current Assets Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoGenomics (NeoGenomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Total Current Assets

Comparable Companies

VCYT MYGN TWST OPK LAB CDNA NEOG CSTL FLGT GH TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

NG9:Germany

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

Executives

Alicia C Olivo	officer: General Counsel	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook	director	C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan	officer: Chief Accounting Officer	HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman	officer: Chief Financial Officer	103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris	officer: President, Enterprise Ops	4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez	director	12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith	officer: Chief Executive Officer	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni	officer: President of Lab Operations	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri	officer: President and CCO, Inivata	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello	officer: VP, Investor Relations	12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie	officer: Principal Accounting Officer	12780 WESTLINKS DRIVE, FORT MYERS FL 33913